| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,1
* Department of Pathology and Laboratory Medicine and
Department of Surgery, MCP Hahnemann University, Philadelphia,Pennsylvania 19102
The role of thrombospondin-1 (TSP-1) in tumor progression is both complex and controversial. It is clear from the literature that the function of TSP-1 in malignancy depends on the presence of other factors and the level of TSP-1 expression in the tumor tissue. High levels of TSP-1 secreted by tumors, which were engineered to overexpress TSP-1, inhibit tumor growth, while anti-sense inhibition of TSP-1 production in certain tumors also inhibits growth. Clearly, the presence of other factors in these experimental systems must be important. The role of TSP-1 in angiogenesis also depends on the levels of TSP-1, the presence and level of angiogenic stimulators such as basic fibroblast growth factor (bFGF), and the localization of TSP-1 in the tissue. Matrix-bound TSP-1 promotes capillary tube formation in the rat aorta model of angiogenesis, while TSP-1 inhibits bFGF- induced angiogenesis in the rat cornea model. The inhibitory effect also depends on the proteolytic state of TSP-1 since the amino terminus promotes angiogenesis in the cornea model, while the remaining140-kDa fragment inhibits bFGF-induced angiogenesis. Both the stimulatory and inhibitory effects of TSP-1 are likely due to upregulation of matrix-degrading enzymes and their inhibitors. These enzymes are critical for maintaining optimal matrix turnover during angiogenesis. These varied TSP-1-dependent mechanisms offer new targets for the development of anti-angiogenic therapeutics for the treatment of a variety of cancers, as well as other pathologies involving inappropriate angiogenesis such as diabetic retinopathy.
Key Words: thrombospondin-1 • adhesion • invasion • angiogenesis
This article has been cited by other articles:
|
|
 |
|
  O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Staniszewska, S. Zaveri, L. D. Valle, I. Oliva, V. L. Rothman, S. E. Croul, D. D. Roberts, D. F. Mosher, G. P. Tuszynski, and C. Marcinkiewicz Interaction of {alpha}9{beta}1 Integrin With Thrombospondin-1 Promotes Angiogenesis Circ. Res., May 11, 2007; 100(9): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aghi, S. D. Rabkin, and R. L. Martuza Angiogenic Response Caused by Oncolytic Herpes Simplex Virus-Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide Cancer Res., January 15, 2007; 67(2): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shoji, H. Koyama, T. Morioka, S. Tanaka, A. Kizu, K. Motoyama, K. Mori, S. Fukumoto, A. Shioi, N. Shimogaito, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes, August 1, 2006; 55(8): 2245 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-J. Lih, W. Wei, and S. N. Cohen Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes Genes & Dev., August 1, 2006; 20(15): 2082 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Sutton, K. O'Byrne, J. C. Goddard, L.-J. Marshall, L. Jones, G. Garcea, A. R. Dennison, G. Poston, D. M. Lloyd, and D. P. Berry Expression of Thrombospondin-1 in Resected Colorectal Liver Metastases Predicts Poor Prognosis Clin. Cancer Res., September 15, 2005; 11(18): 6567 - 6573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Iida, M Honda, H F Kawai, T Yamashita, Y Shirota, B-C Wang, H Miao, and S Kaneko Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma Gut, June 1, 2005; 54(6): 843 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Renshaw, R. M. Orr, M. I. Walton, R. te Poele, R. D. Williams, E. V. Wancewicz, B. P. Monia, P. Workman, and K. Pritchard-Jones Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival Mol. Cancer Ther., November 1, 2004; 3(11): 1467 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sengupta, S. Banerjee, N. K. Saxena, and S. K. Banerjee Thombospondin-1 Disrupts Estrogen-Induced Endothelial Cell Proliferation and Migration and Its Expression Is Suppressed by Estradiol Mol. Cancer Res., March 1, 2004; 2(3): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Zhang, Y. Su, O. V. Volpert, and G. F. V. Woude Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation PNAS, October 28, 2003; 100(22): 12718 - 12723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Alaoui-Jamali, D. J. Song, N. Benlimame, L. Yen, X. Deng, M. Hernandez-Perez, and T. Wang Regulation of Multiple Tumor Microenvironment Markers by Overexpression of Single or Paired Combinations of ErbB Receptors Cancer Res., July 1, 2003; 63(13): 3764 - 3774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
